Jacob M C, Piccinni M P, Bonnefoix T, Sotto M F, Couderc P, Bensa J C, Sotto J J
Laboratoire de recherche d'immunopathologie tumorale, hôpital A. Michallon, Grenoble, France.
Blood. 1990 Mar 1;75(5):1154-62.
Tumor-infiltrating T lymphocytes (TIL-T) are always present in B-cell-derived non-Hodgkin's lymphoma (NHL). In this investigation, we explored the possibility that collaboration might exist between these cells. TIL-T were isolated from 39 lymph nodes of patients with NHL. In most of the cases, few of them (less than 10%) possessed surface activation receptors CD25 or OKT9. In 80% of the cases, they proliferated in response to recombinant interleukin-2 (rIL-2), but the degree of proliferation was often low as compared with control populations. The influence of irradiated autologous malignant cells on the TIL-T proliferation in response to rIL-2 (40 U/mL) was also investigated: in 38% of the cases, this proliferation was not modified (group O), and in 41% it was higher (group +) and in 21% it was lower (group -). The mechanism of this immune response (specific or not) is not elucidated at present. The definition of these groups was statistically correlated with different parameters of the disease: (1) percentage of TIL-T was higher in group + (44% +/- 17%) than in group O (31% +/- 18%) and group - (24% +/- 15%); (2) B-cell proliferation in centrofollicular lymphomas was more frequently nodular or nodular and diffuse in group + (83%) and O (55%) than in group - (0%); (3) low-grade malignancies in the Working Formulation were more frequent in group + (75%) than in group O (60%) or group - (12%); (4) favorable prognosis evaluated with the Grenoble cytologic classification was more frequent in group + and O (87%) than in group - (12%); (5) actuarial survival curves showed a significantly better prognosis for patients in group +.
肿瘤浸润性T淋巴细胞（TIL-T）始终存在于B细胞来源的非霍奇金淋巴瘤（NHL）中。在本研究中，我们探讨了这些细胞之间可能存在协作的可能性。从39例NHL患者的淋巴结中分离出TIL-T。在大多数病例中，它们中很少（不到10%）具有表面活化受体CD25或OKT9。在80%的病例中，它们对重组白细胞介素-2（rIL-2）有增殖反应，但与对照群体相比，增殖程度通常较低。还研究了经辐照的自体恶性细胞对TIL-T在rIL-2（40 U/mL）刺激下增殖的影响：在38%的病例中，这种增殖未改变（O组），41%的病例中增殖更高（+组），21%的病例中增殖更低（-组）。目前尚不清楚这种免疫反应（是否具有特异性）的机制。这些组别的定义与疾病的不同参数在统计学上相关：（1）+组（44%±17%）的TIL-T百分比高于O组（31%±18%）和-组（24%±15%）；（2）在+组（83%）和O组（55%）中，中心滤泡性淋巴瘤中的B细胞增殖比-组（0%）更频繁地呈结节状或结节状及弥漫性；（3）工作分类法中的低级别恶性肿瘤在+组（75%）中比O组（60%）或-组（12%）更常见；（4）根据格勒诺布尔细胞学分类评估的良好预后在+组和O组（87%）中比-组（12%）更常见；（5）精算生存曲线显示+组患者的预后明显更好。
